Skip to main content
Fig. 1 | Clinical Epigenetics

Fig. 1

From: Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia

Fig. 1

DNA methylation and response to guadecitabine. a Unsupervised hierarchical clustering of 116 r/r AML patients based on 2774 hypervariable sites (standard deviation > 10%) divided the cases into three clusters which were normal-like, CIMP-like, and intermediate methylation. b Kaplan-Meier survival analysis of 116 cases based on the clusters derived in a. There was a trend for longer survival in the “normal-like” cluster, but this trend was not statistically significant (p = 0.21 by log-rank test)

Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us